Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - le myélome multiple - agents antinéoplasiques - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Canada - français - Health Canada

janssen inc - téclistamab - solution - 30mg - téclistamab 30mg

Canada - français - Health Canada

janssen inc - téclistamab - solution - 153mg - téclistamab 153mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - teclistamabum - solution injectable - teclistamabum 30 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 3 ml corresp. natrium 0.75 mg. - multiples myelom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - teclistamabum - solution injectable - teclistamabum 153 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.7 ml corresp. natrium 0.43 mg. - multiples myelom - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - le myélome multiple - agents antinéoplasiques - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - belantamabum mafodotinum - poudre pour solution à diluer pour perfusion - praeparatio cryodesiccata: belantamabum mafodotinum 100 mg, natrii citras dihydricus, acidum citricum, trehalosum dihydricum, dinatrii edetas, polysorbatum 80, pro vitro corresp. natrium 3.15 mg. - multiples myelom - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - mélanome - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.